Institution
Purdue Pharma
Company•Pickering, Ontario, Canada•
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..
Topics: Buprenorphine, Chronic pain, Oxycodone, Hydrocodone, Controlled release
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Based on the reductions in daily frequency of incontinence and micturition following 4-weeks treatment, CR oxybutynin was at least as effective as the patients' previous dose of IR oxy butynin (mean dose: 6.7 ± 2.5 mg/day).
Abstract: SUMMARYObjective: To conduct a preliminary evaluation of a new oral formulation of controlled-release (CR) oxybutynin tablet taken once-daily in patients with urinary urge incontinence.Research design and methods: A single-centre, open-label, 8-week study was conducted. Patients with urodynamically-confirmed detrusor instability, micturition frequency (> 8 voids/day) and/or urinary incontinence (> 2 incontinence periods/day) were enrolled. The study duration was 8 weeks: patients received IR oxybutynin (2.5-5 mg bid) for 2 weeks, followed by a 2-week washout/baseline period to avoid carryover effects, and oral CR oxybutynin (15 mg OD) for 4 weeks. Daily void frequency, fluid intake, urinary incontinence episodes, and spontaneously reported adverse events were recorded in a daily diary for five consecutive days in each treatment period.Results: Of 12 enrolled patients, 9 patients completed the study and were evaluable for efficacy; all patients were evaluable for safety. Compared to baseline/washout, CR ox...
1 citations
••
1 citations
•
04 Dec 2013TL;DR: The present invention is directed to Buprenorphine Analog compounds of the Formula 1, Formula II, Formula III, Formula IV, and Formula V, wherein R 1, R2, R3a, R 3b, R,15a,R15b, X, Q, G, and Y are as defined in this article.
Abstract: The present invention is directed to Buprenorphine Analog compounds of the Formula 1, Formula II, Formula III, Formula IV, and Formula V, wherein R1, R2, R3a, R3b, R,15a, R15b, X, Q, G, and Y are as defined herein. Compounds of the Invention are useful for treating pain and other conditions modulated by activity of opioid receptors.
1 citations
••
1 citations
••
TL;DR: The 2016 SPS salary survey results showcased significant diversity regarding factors that can influence salary compensation within this discipline and revealed the level of scientific specialization embedded within the organization, presently uniquely positioned to support the dynamic career paths of current and future safety pharmacologists.
1 citations
Authors
Showing all 622 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gideon Koren | 129 | 1994 | 81718 |
Asbjørn Mohr Drewes | 67 | 656 | 17287 |
Hilary L. Surratt | 44 | 169 | 7586 |
Ronald M. Burch | 42 | 108 | 5897 |
John F. W. Keana | 41 | 234 | 6349 |
Sui Xiong Cai | 39 | 91 | 4492 |
Howard D. Chilcoat | 39 | 91 | 8739 |
Sidney H. Schnoll | 37 | 88 | 5336 |
Paul Coplan | 36 | 121 | 4149 |
Benjamin Oshlack | 32 | 95 | 3902 |
Nabarun Dasgupta | 30 | 100 | 3366 |
Donald J. Kyle | 29 | 150 | 2390 |
Nancy C. Lan | 29 | 50 | 3597 |
Christopher D. Breder | 28 | 50 | 6748 |
Michael F. Schneider | 27 | 53 | 4862 |